Keros Therapeutics (KROS) Equity Ratio (2019 - 2025)
Keros Therapeutics' Equity Ratio history spans 7 years, with the latest figure at 0.9 for Q4 2025.
- For Q4 2025, Equity Ratio fell 3.37% year-over-year to 0.9; the TTM value through Dec 2025 reached 0.9, down 3.37%, while the annual FY2025 figure was 0.9, 3.37% down from the prior year.
- Equity Ratio reached 0.9 in Q4 2025 per KROS's latest filing, down from 0.95 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.97 in Q2 2021 to a low of 0.9 in Q4 2025.
- Average Equity Ratio over 5 years is 0.93, with a median of 0.93 recorded in 2022.
- Peak YoY movement for Equity Ratio: surged 334.82% in 2021, then dropped 5.08% in 2022.
- A 5-year view of Equity Ratio shows it stood at 0.95 in 2021, then fell by 5.08% to 0.9 in 2022, then dropped by 0.72% to 0.9 in 2023, then increased by 3.36% to 0.93 in 2024, then fell by 3.37% to 0.9 in 2025.
- Per Business Quant, the three most recent readings for KROS's Equity Ratio are 0.9 (Q4 2025), 0.95 (Q3 2025), and 0.93 (Q2 2025).